George, very encouraging...

but, some SGLT2i are also going after the heart failure market (and other endpoints) with patients suffering from CKD:

https://twitter.com/edgarvlermamd/status/1252767622090932225

there should be 4 slides that outline what Empagliflozin and Canagliflozin are going after.  So, in my humble opinion, we do have some competition (I think there are other examples too)...unless somebody shows me I'm way off the mark??